Juvenile Idiopathic Arthritis clinical trials at UCSF
3 in progress, 2 open to eligible people
Adalimumab in JIA-associated Uveitis Stopping Trial
open to eligible people ages 2 years and up
The proposed study is a stratified, block-randomized, double-masked, controlled trial to determine the feasibility of discontinuing adalimumab treatment in patients with quiescent uveitis associated with juvenile idiopathic arthritis (JIA) or ANA-positive cronic anterior uveitis (CAU).
San Francisco, California and other locations
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
open to eligible people ages 2-16
This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.
San Francisco, California and other locations
Pediatric Arthritis Study of Certolizumab Pegol
Sorry, in progress, not accepting new patients
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
San Francisco, California and other locations
Our lead scientists for Juvenile Idiopathic Arthritis research studies include Nisha Acharya.
Last updated: